Immunosuppression Only Conditioning ( DrugBank: - )

---

1 disease

ID	Disease name (Link within this page)	Number of trials
65	Primary immunodeficiency	2

65. Primary immunodeficiency

---

Clinical trials : 500 /  Drugs : 614 - (DrugBank : 119) / Drug target genes : 92 - Drug target pathways : 217

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03663933 (ClinicalTrials.gov)	September 4, 2018	7/9/2018	Allogeneic Hematopoietic Cell Transplantation for Disorders of T-cell Proliferation and/or Dysregulation	Phase II Trial of Allogeneic Hematopoietic Cell Transplantation for Disorders of T-cell Proliferation and/or Dysregulation	Lymphoproliferative Disorders;Autoimmune Lymphoproliferative;Primary T-cell Immunodeficiency Disorders;Immune System Diseases;Common Variable Immunodeficiency	Drug: Immunosuppression Only Conditioning;Drug: Reduced Intensity Conditioning;Drug: GVHD Prophylaxis;Procedure: Allogeneic HSC	National Cancer Institute (NCI)	NULL	Recruiting	4 Years	N/A	All	177	Phase 2	United States
2	NCT02579967 (ClinicalTrials.gov)	November 19, 2015	16/10/2015	Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies	Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies	Primary T-cell Immunodeficiency Disorders;Common Variable Immunodeficiency;Immune System Diseases;Autoimmune Lymphoproliferative;Lymphoproliferative Disorders	Drug: Immunosuppression Only Conditioning -Closed with amendment L;Drug: Reduced Intensity Conditioning;Drug: Myeloablative Conditioning-Closed with amendment L;Drug: GVHD Prophylaxis;Procedure: Allo BMT	National Cancer Institute (NCI)	NULL	Recruiting	4 Years	75 Years	All	224	Phase 2	United States